| Bioactivity | PET-16 is a selective HSP70 inhibitor that binds to an allosteric pocket of the substrate-binding domain. PET-16 inhibits the ability of HSP70 to cycle between ATP-bound and ADP-bound states. PET-16 induces apoptosis in multiple myeloma[1]. |
| Invitro | PET-16（0.01-100 μM；72 小时）在多发性骨髓瘤 (MM) 细胞系中表现出细胞毒性，HSP70 稳态水平最高的细胞系表现出最低的 IC50[1]。PET-16（3 μM；24 小时）诱导多发性骨髓瘤细胞凋亡，同时伴有蛋白毒性应激[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. 0 --> PET-16 相关抗体: Cell Viability Assay[1] Cell Line: |
| In Vivo | PET-16（5-10 mg/kg；腹腔注射；每周两次；持续 3 周）显著降低小鼠的 p-FAK 和 BRAF 染色[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: |
| CAS | 34387-64-9 |
| Formula | C26H20BrP |
| Molar Mass | 443.31 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Charvann K Bailey, et al. Efficacy of the HSP70 inhibitor PET-16 in multiple myeloma. Cancer Biol Ther. 2015;16(9):1422-6. [2]. Anna Budina-Kolomets, et al. HSP70 Inhibition Limits FAK-Dependent Invasion and Enhances the Response to Melanoma Treatment with BRAF Inhibitors. Cancer Res. 2016 May 1;76(9):2720-30. |